Pneumococcal conjugate second or third-dose vaccines (PCVc) in Americas (WHO region)
Americas (WHO region): Pneumococcal conjugate second or third-dose vaccines (PCVc) was 80.0% in 2025. β² Rising
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Americas (WHO region), 2008β2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in Americas (WHO region) stood at 80.0%.
That represents a change of down 1.2% on the previous year and down 5.9% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Americas (WHO region) peaked at 85.0% in 2015 and was at its lowest, 29.0%, in 2008.
The long-run direction has been consistently rising across the 18 years of available data.
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 31.5% | 29.0% | 34.0% | 2 |
| 2010s | 77.3% | 51.0% | 85.0% | 10 |
| 2020s | 78.0% | 75.0% | 81.0% | 6 |
More health data for Americas (WHO region)
- Diphtheria - number of reported cases 72 (2025)
- Total tetanus - number of reported cases 385 (2025)
- Pertussis - number of reported cases 24,640 (2025)
- Measles - number of reported cases 12,380 (2025)
- Neonatal tetanus - number of reported cases 23 (2025)
- Under-five mortality rate 12.64 (2024)
- Obesity among adults, BMI β₯ 30 kg/m2 (crude estimate) 35.0% (2024)
- Overweight among children and adolescents, BMI-for-age > +1 standard 39.2% (2024)
- Obesity among children and adolescents, BMI-for-age > +2 standard 19.7% (2024)
- Overweight among adults, BMI β₯ 25 kg/m2 (age-standardized estimate) 68.1% (2024)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Americas (WHO region)?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Americas (WHO region) was 80.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Americas (WHO region)?
- The highest recorded value was 85.0% in 2015.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Americas (WHO region)?
- The lowest recorded value was 29.0% in 2008.
- How does Americas (WHO region) rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Americas (WHO region) ranks 5th out of 11 groups with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Americas (WHO region)?
- Over the last ten years it is down 5.9%. The long-run trend across the full record is rising.
- Where does this Americas (WHO region) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV Β· JSON β 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).